Agilent announces quarterly dividend of 24.8 cents

Published 19/02/2025, 22:14
Agilent announces quarterly dividend of 24.8 cents

SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE: NYSE:A), a provider of analytical and clinical laboratory technologies, has declared a quarterly dividend payment to its shareholders. The dividend of 24.8 cents per share of common stock is scheduled to be distributed on April 23, 2025, to shareholders on record as of April 1, 2025. According to InvestingPro data, Agilent has maintained dividend payments for 13 consecutive years, with a current yield of 0.73% and impressive dividend growth of 10.22% over the last twelve months.

This announcement follows Agilent’s fiscal year 2024 performance, where the company reported revenue of $6.51 billion and currently employs approximately 18,000 people globally. With a market capitalization of $39.13 billion and a strong current ratio of 2.09, InvestingPro analysis indicates the company is currently trading above its Fair Value. The company’s dividend program is subject to periodic review and approval by the board of directors, and future dividends will depend on such determinations.

Agilent, known for its range of solutions including instruments, software, services, and expertise, aims to deliver insights and innovations that assist customers in addressing complex scientific questions. The company maintains a strong financial health rating according to InvestingPro, which offers 12 additional valuable insights about Agilent’s performance and prospects in its comprehensive Pro Research Report, available exclusively to subscribers.

The forward-looking statements in the press release, related to the company’s dividend program and future payment obligations, are subject to various risks and uncertainties. These could potentially cause actual results to differ from management’s expectations. Agilent cautions that these forward-looking statements are based on current information and assumptions and commits to no obligation to update or revise any such statements publicly.

Investors and stakeholders are reminded that this information is based on a press release statement and that future dividend payments are not guaranteed but are contingent upon approval by the company’s board of directors.

In other recent news, Danaher Corporation (NYSE:DHR) is anticipating its upcoming earnings report following the strong financial results of Sartorius AG (ETR:SATG), which reported better-than-expected adjusted EBITDA and a forecast for moderate sales revenue growth by 2025. The positive ripple effect from Sartorius’s performance has also influenced other companies in the life sciences sector, including Thermo Fisher Scientific (NYSE:TMO), Repligen (NASDAQ:RGEN), and Agilent Technologies. Meanwhile, Waters Corp (NYSE:WAT). has been impacted by new export controls announced by the U.S. Commerce Department, which target biotechnology equipment to prevent use by China in military applications. This development has led to a decline in stock prices for several companies in the sector, including Danaher, Thermo Fisher, and Agilent.

Agilent Technologies recently held an Investor Day where Stifel reiterated its Buy rating, emphasizing the company’s strategic priorities such as operating margin expansion and PFAS testing. Baird also reaffirmed an Outperform rating for Agilent, highlighting the company’s long-term revenue and EPS growth targets. Additionally, Bernstein SocGen Group maintained a Market Perform rating for Agilent, noting the company’s "Ignite" transformation strategy and reaffirmed financial goals for 2025 and beyond. These ratings reflect confidence in Agilent’s ability to navigate current challenges and capitalize on growth opportunities in the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.